Opendata, web and dolomites

ConcePTION SIGNED

Building an ecosystem for better monitoring and communicating of medication safety in pregnancy and breastfeeding: validated and regulatory endorsed workflows for fast, optimised evidence generation

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ConcePTION" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAIR MEDISCH CENTRUM UTRECHT 

Organization address
address: HEIDELBERGLAAN 100
city: UTRECHT
postcode: 3584 CX
website: www.umcutrecht.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 28˙778˙406 €
 EC max contribution 15˙299˙991 € (53%)
 Programme 1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
 Code Call H2020-JTI-IMI2-2017-13-two-stage
 Funding Scheme IMI2-RIA
 Starting year 2019
 Duration (year-month-day) from 2019-04-01   to  2024-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAIR MEDISCH CENTRUM UTRECHT NL (UTRECHT) coordinator 2˙782˙332.00
2    UNIVERSITY OF ULSTER UK (COLERAINE) participant 1˙242˙181.00
3    KATHOLIEKE UNIVERSITEIT LEUVEN BE (LEUVEN) participant 1˙052˙746.00
4    UPPSALA UNIVERSITET SE (UPPSALA) participant 980˙421.00
5    STICHTING LAREB NL (S HERTOGENBOSCH) participant 854˙410.00
6    ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA IT (BOLOGNA) participant 832˙760.00
7    UNIVERSITETET I OSLO NO (OSLO) participant 727˙915.00
8    CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE FR (TOULOUSE CEDEX 3) participant 652˙703.00
9    STICHTING ENTIS (EUROPEAN NETWORK TERATOLOGY INFORMATION SERVICES) FOUNDATION NL (HERTOGENBOSCH) participant 568˙816.00
10    THE EUROPEAN INSTITUTE FOR INNOVATION THROUGH HEALTH DATA BE (STROMBEEK-BEVER) participant 466˙011.00
11    THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST UK (NEWCASTLE-UPON-TYNE) participant 456˙193.00
12    ST GEORGE'S HOSPITAL MEDICAL SCHOOL UK (LONDON) participant 400˙423.00
13    UNIVERSITE DE GENEVE CH (GENEVE) participant 372˙755.00
14    AGENZIA REGIONALE DI SANITA IT (FIRENZE) participant 359˙110.00
15    BIONOTUS BE (TEMSE) participant 355˙143.00
16    THE UNIVERSITY OF MANCHESTER UK (MANCHESTER) participant 338˙000.00
17    BIOBANKS AND BIOMOLECULAR RESOURCES RESEARCH INFRASTRUCTURE CONSORTIUM (BBMRI-ERIC) AT (GRAZ) participant 328˙420.00
18    THE SYNERGIST BE (BRUXELLES) participant 286˙336.00
19    ACADEMISCH ZIEKENHUIS GRONINGEN NL (GRONINGEN) participant 260˙938.00
20    ORCION BV NL (ASTEN) participant 235˙313.00
21    UNIVERSITY OF KWAZULU-NATAL ZA (WESTVILLE) participant 229˙223.00
22    TERVEYDEN JA HYVINVOINNIN LAITOS FI (HELSINKI) participant 207˙038.00
23    EUROPEAN INSTITUTE OF WOMEN'S HEALTH COMPANY LIMITED BY GUARANTEE IE (DUBLIN) participant 135˙160.00
24    REGION STOCKHOLM SE (STOCKHOLM) participant 119˙911.00
25    SWANSEA UNIVERSITY UK (SWANSEA) participant 119˙036.00
26    ELEVATE BV NL (UTRECHT) participant 110˙918.00
27    MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY UK (LONDON) participant 108˙218.00
28    RIJKSINSTITUUT VOOR VOLKSGEZONDHEID EN MILIEU NL (BILTHOVEN) participant 107˙321.00
29    EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE BE (BRUSSELS) participant 94˙992.00
30    THE EUROPEAN MEDICINES AGENCY NL (AMSTERDAM) participant 85˙000.00
31    UNIVERSITA DEGLI STUDI DI FERRARA IT (FERRARA) participant 83˙586.00
32    FUNDACION PARA EL FOMENTO DE LA INVESTIGACION SANITARIA Y BIOMEDICA DE LA COMUNITAT VALENCIANA ES (VALENCIA) participant 79˙868.00
33    CONSIGLIO NAZIONALE DELLE RICERCHE IT (ROMA) participant 70˙722.00
34    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 68˙207.00
35    TTOPSTART BV NL (UTRECHT) participant 67˙130.00
36    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 60˙721.00
37    ABBVIE INC US (NORTH CHICAGO IL) participant 0.00
38    BRISTOL-MYERS SQUIBB COMPANY CORP US (NEW YORK) participant 0.00
39    COVANCE LABORATORIES LTD UK (HARROGATE) participant 0.00
40    Eli Lilly and Company Limited UK (Basingstoke) participant 0.00
41    ELLEGAARD GOTTINGEN MINIPIGS AS DK (DALMOSE) participant 0.00
42    GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD. UK (BRENTFORD) participant 0.00
43    JANSSEN PHARMACEUTICA NV BE (BEERSE) participant 0.00
44    MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN DE (DARMSTADT) participant 0.00
45    NOVARTIS PHARMA AG CH (BASEL) participant 0.00
46    NOVO NORDISK A/S DK (BAGSVAERD) participant 0.00
47    PFIZER LIMITED UK (SANDWICH) participant 0.00
48    SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT FR (Chilly Mazarin) participant 0.00
49    TAKEDA DEVELOPMENT CENTRE EUROPE LTD UK (LONDON) participant 0.00
50    TEVA PHARMACEUTICAL INDUSTRIES LIMITED IL (PETACH TIVKA) participant 0.00
51    UCB BIOPHARMA SRL BE (BRUXELLES) participant 0.00

Map

 Project objective

ConcePTION partners have united around a shared vision that we have a societal obligation to radically and rapidly reduce uncertainty about the safety of medication use in pregnancy and lactation. What do we deliver? ConcePTION aims to create a paradigm shift in how we study medication safety in pregnancy. We will establish (1) a successful, sustainable open-science based EU non-proprietary ecosystem of public and private stakeholders, pregnant women and researchers to generate and disseminate timely and reliable evidence on drugs across maternal, neonatal and long term outcomes of medication exposure in pregnancy and breastfeeding (2) a catalogue with fully characterized data sources for rapid selection of suitable data sources; 3) operational, business, network, information and data governance models, (4) quality assured and tested methodological approaches, analytical tools and data platforms allowing for distributed analyses, (5) procedures and tools for collection of digital data and samples directly from pregnant women, (6) In vitro, in silico and in vivo models for prediction of drug transfer in human milk, (7) a biobank and analytical network for quantification of drug in human milk, (8) best practice documents endorsed by regulators and health authorities and (9) a web-based drug information knowledge bank.

How do we deliver? (1) Experienced leaders, able to manage challenging networks and public-public or public-private partnerships. (2) Defragmentation by connecting all key stakeholders and EU networks in this area. (3) Re-use of data, tools and foreground from prior European commission funded projects. (4) Connecting to leaders of similar initiatives in the USA, Canada, Asia and other parts of the world. (5) Systematic consensus & endorsement building. (6) Quality throughout as a precondition to trust the results and information by all users.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CONCEPTION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CONCEPTION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.7.)

EBOVAC3 (2018)

Bringing a prophylactic Ebola vaccine to licensure

Read More  

RespiriTB (2019)

Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors

Read More  

GNA NOW (2019)

NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW

Read More